The Trump administration has suspended research grants totaling $210 million to Princeton University as part of an ongoing ...

Hate leafleting has become an increasingly common means for extremist groups to espouse hateful messages and intimidate ...

A woman will avoid jail time after investigators say she vandalized multiple cars of pro-Palestinian protestors outside of an ...

On 9 April, during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) meeting, Remegen announced exciting results from a Phase III clinical trial evaluating the efficacy ...

The report found more than 1,000 hate incidents over the past five years. Twenty-six Illinois counties had at least six hate ...

The Department of Homeland Security on Wednesday said it immediately will begin screening visa applicants' social media for ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

Jiang Yi, a 30-year-old woman from Zhejiang province, was diagnosed with cervical cancer just three months ago.

The report found more than 1,000 hate incidents over the past five years. Twenty-six Illinois counties had at least six hate incidents each, including Coles, Macon, McLean and Rock Island counties.

YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and ...

The Arthur D. Little 2025 CEO Insights Study interviewed 309 global CEOs leading companies with a turnover of more than $1 ...

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...